For example, CRISPR-mediated knockout of immune checkpoint molecules, such as programmed cell death protein 1(PD-1), demonstrated promising antitumor activity of CAR-T cells by inhibiting their exhaustion and enhancing persistence in the hostile tumour microenvironment (TME) (Yan et al., 2024). The gene discussed is PDCD1; the disease is neoplasm.